These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34751039)

  • 41. Immune checkpoint inhibitors in melanoma.
    Carlino MS; Larkin J; Long GV
    Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients.
    Maggiore U; Pascual J
    Adv Chronic Kidney Dis; 2016 Sep; 23(5):312-316. PubMed ID: 27742386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
    Front Immunol; 2021; 12():672521. PubMed ID: 34177913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
    Schuiveling M; Tonk EHJ; Verheijden RJ; Suijkerbuijk KPM
    Cancer Immunol Immunother; 2021 May; 70(5):1491-1496. PubMed ID: 32929554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gene Expression Profiling in Kidney Transplant Recipients on Immune Checkpoint Inhibitors: More than Meets the Eye.
    Jethwani P; Shirali AC
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1315-1317. PubMed ID: 34497109
    [No Abstract]   [Full Text] [Related]  

  • 50. Resistance mechanisms to checkpoint inhibitors.
    Weiss SA; Sznol M
    Curr Opin Immunol; 2021 Apr; 69():47-55. PubMed ID: 33676271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
    Sheng Y; Tong L; Geyu L
    Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.
    Manohar S; Thongprayoon C; Cheungpasitporn W; Markovic SN; Herrmann SM
    Kidney Int Rep; 2020 Feb; 5(2):149-158. PubMed ID: 32043028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of immune checkpoint inhibitors for in-transit melanoma.
    Nan Tie E; Lai-Kwon J; Rtshiladze MA; Na L; Bozzi J; Read T; Atkinson V; Au-Yeung G; Long GV; McArthur GA; Sandhu S; Saw R; Walpole E; Menzies A; Smithers M; Gyorki DE
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
    Hanania HL; Lewis DJ
    J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
    Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
    Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
    Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
    Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
    Gambichler T; Hessam S; Lüttringhaus T; Boms S
    Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials.
    Akhbariyoon H; Azizpour Y; Esfahani MF; Firoozabad MSM; Rad MR; Esfahani KS; Khoshavi N; Karimi N; Shirinisaz A; Abedi F; Rad MR; Sharifi P
    Clin Immunol; 2021 Nov; 232():108873. PubMed ID: 34688855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.